Macrophage Therapeutics is using its Manocept technology to engineer novel compounds that target activated macrophages by binding to the mannose receptor or CD206 on the macrophage cell surface with high binding affinity of 3X10-11 affinity. These synthetic compounds have antibody-like properties but with advantages that can improve dosing options.
The Manocept platform is a clinically-proven technology currently being used in an FDA-approved product that has potential broad therapeutic application across several disease areas including cancer, autoimmune, CNS, cardiovascular, inflammatory and infectious diseases. Preclinical studies are ongoing in many of these diseases. The Manocept technology is proprietary and patent protected, and Navidea has licensed all of their intellectual property to Macrophage Therapeutics for all therapeutic applications.
Manocept’s mannose moiety acts like a global positioning system, targeting the CD206 receptor found on activated macrophages.
Manocept’s glucose backbone acts like a missile, delivering a warhead to its target.
A payload, or warhead, such as chemotherapeutics, immune-modulators, isotopes or other agents, can be linked to the missile and delivered to activated macrophages.
Our proprietary technology delivers a therapeutic payload that can:
Gordon S. Alternative activation of macrophages. Nature Rev. Immunol 2003;3:23–35.
Mills, C., & Ley, K. (2014). M1 and M2 Macrophages: The Chicken and the Egg of Immunity. J Innate Immun Journal of Innate Immunity, 716-726.
Mosser, D., & Edwards, J. (2008). Exploring the full spectrum of macrophage activation. Nat Rev Immunol Nature Reviews Immunology, 460-460.
Geissmann, F., Manz, M., Jung, S., Sieweke, M., Merad, M., & Ley, K. (2010). Development of Monocytes, Macrophages, and Dendritic Cells. Science, 656-661.
Mills, C., Kincaid, K., Alt, J., Heilman, M., & Hill, A. (2000). M-1/M-2 Macrophages and the Th1/Th2 Paradigm. The Journal of Immunology, 6166-6173.
Mills, C. (2012). M1 and M2 Macrophages: Oracles of Health and Disease. Crit Rev Immunol Critical Reviews in Immunology, 463-488.
Chen, Peiwen, Matilde Cescon, and Paolo Bonaldo. “Autophagy-mediated Regulation of Macrophages and Its Applications for Cancer.” Autophagy 10.2 (2013): 192-200.
Rozali, Esdy N., Stanleyson V. Hato, Bruce W. Robinson, Richard A. Lake, and W. Joost Lesterhuis. “Programmed Death Ligand 2 in Cancer-Induced Immune Suppression.” Clinical and Developmental Immunology 2012 (2012): 1-8.
Shalhoub, Joseph, Mika A. Falck-Hansen, Alun H. Davies, and Claudia Monaco. “Innate Immunity and Monocyte-macrophage Activation in Atherosclerosis.” Journal of Inflammation J Inflamm 8.1 (2011)Tabas, Ira. “Macrophage Death and Defective Inflammation Resolution in Atherosclerosis.” Nat Rev Immunol Nature Reviews Immunology 10.2 (2010): 117.Hirata, Yoichiro, Minoru Tabata, Hirotsugu Kurobe, Tatsuo Motoki, Masashi Akaike, Chika Nishio, Mayuko Higashida, Hiroaki Mikasa, Yutaka Nakaya, Shuichiro Takanashi, Takashi Igarashi, Tetsuya Kitagawa, and Masataka Sata. “Coronary Atherosclerosis Is Associated With Macrophage Polarization in Epicardial Adipose Tissue.” Journal of the American College of Cardiology 58.3 (2011): 248-55.Hadri, K. E., D. F. D. Mahmood, D. Couchie, I. Jguirim-Souissi, F. Genze, V. Diderot, T. Syrovets, O. Lunov, T. Simmet, and M. Rouis. “Thioredoxin-1 Promotes Anti-Inflammatory Macrophages of the M2 Phenotype and Antagonizes Atherosclerosis.” Arteriosclerosis, Thrombosis, and Vascular Biology 32.6 (2012): 1445-452.Bukrinsky, Michael, and Dmitri Sviridov. “HIV and Cardiovascular Disease: Contribution of HIV-Infected Macrophages to Development of Atherosclerosis.” Plos Med PLoS Medicine 4.1 (2007)
Coscoy, Laurent. “Immune Evasion by Kaposi’s Sarcoma-associated Herpesvirus.” Nat Rev Immunol Nature Reviews Immunology 7.5 (2007): 391-401.
Exploitation of the Mannose Receptor (CD206) in Infectious Disease Diagnostics and Therapeutics. A. Azad, M. Rajaram and L. Schlesinger; J. Cytol Mol Biol 2014
Fletcher, N., Sutaria, R., Jo, J., Barnes, A., Blahova, M., Meredith, L., . . . Mckeating, J. (2014). Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology, 1320-1330.Navarro, L., Wree, A., Povero, D., Berk, M., Eguchi, A., Ghosh, S., . . . Feldstein, A. (2014). Arginase 2 deficiency results in spontaneous steatohepatitis: A novel link between innate immune activation and hepatic de novo lipogenesis. Journal of Hepatology, 412-420.Heydtmann, M. (2008). Macrophages in Hepatitis B and Hepatitis C Virus Infections. Journal of Virology, 2796-2802.Revie, D. (2014). Role of macrophages and monocytes in hepatitis C virus infections. World Journal of Gastroenterology WJG, 2777-2777.Pelletier, S., Bedard, N., Said, E., Ancuta, P., Bruneau, J., & Shoukry, N. (2013). Sustained Hyperresponsiveness of Dendritic Cells Is Associated with Spontaneous Resolution of Acute Hepatitis C. Journal of Virology, 6769-6781.
Xu, Y., Jia, L., Quinn, B., Zamzow, M., Stringer, K., Aronow, B., . . . Grabowski, G. (2011). Global gene expression profile progression in Gaucher disease mouse models. BMC Genomics, 20-20.